Jim Cramer's Mad Dash: Celgene and Morgan Stanley Still Have Upside

NEW YORK (TheStreet) -- Shares of Celgene (CELG) are higher on Wednesday, after posting positive gains on Tuesday when many other stocks saw losses. Jim Cramer attributed these gains to the Food and Drug Administration's approval of the company's psoriasis treatment, which occurred Tuesday. 

On CNBC's "Cramer's Mad Dash" segment, Cramer, the co-manager of the Action Alerts PLUS portfolio, added that the company's work in treating breast cancer and pancreatic cancer is also a positive. 

The company could also emerge with an important arthritis treatment in the future, and "Celgene is not done going higher," he said. 

Turning to Morgan Stanley (MS) , the stock was downgraded by J.P. Morgan. The analyst suggests that the stock is expensive and that UBS AG (UBS) is more attractive. 

Cramer disagreed with the call, saying he likes Morgan Stanley. The company has a "great business" and the stock still has upside, he concluded.

 

-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

Breaking: Bill Cosby Found Guilty on All Counts in Sexual Assault Retrial

Breaking: Bill Cosby Found Guilty on All Counts in Sexual Assault Retrial

Earnings Season Is Simply Out of Control Madness - How Are You Surviving?

Earnings Season Is Simply Out of Control Madness - How Are You Surviving?

Why Ether and Ripple -- But Not Bitcoin -- Prices Might Come Under Pressure Soon

Why Ether and Ripple -- But Not Bitcoin -- Prices Might Come Under Pressure Soon

Daily Chatter: Here's Where the Markets Stand After Tuesday's Beating

Daily Chatter: Here's Where the Markets Stand After Tuesday's Beating

3 New Investing Myths That Must Be Busted

3 New Investing Myths That Must Be Busted